Monoclonal antibodies
US8337842B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 4, 2009 |
| Grant date | Dec 25, 2012 |
| Priority date | — |
| Expiry date | Nov 22, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides heterochimeric antibodies and/or fragments thereof comprising (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region sequences wholly or substantially corresponding to sequences found in antibodies from a target species which is different from the donor species; and (iii) heavy and/or light chain variable framework sequences which contain at least three non-CDR residues corresponding to sequences found in antibodies from a target species and at least three contiguous non-CDR residues corresponding to sequences found in antibodies from a donor species. The invention further provides antibody to canine or feline or equine antigens, e.g., CD20 or CD52, and methods of making and using antibodies as described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.